文献速递头颈外科咽喉与嗓音

声门癌环状软骨上部分喉切除术联合与不联合新辅助化疗的比较

Supracricoid Partial Laryngectomy With and Without Neoadjuvant Chemotherapy in Glottic Cancer.
PubMed 文献 · Laryngoscope · 2021-06-26

该回顾性研究比较了初始行环状软骨上喉部分切除术的患者与接受新辅助化疗后手术的T3N0声门型鳞癌伴杓状软骨固定患者,两组均行双侧选择性颈淋巴结清扫和Delphian淋巴结探查。结果显示两组在器官保留、无病生存、总生存和癌症特异性生存方面无统计学差异,新辅助化疗可使功能预后差或不适合器官保留的患者安全接受保守手术。

要点

  • 新辅助化疗联合环状软骨上部分喉切除术是肿瘤学安全的手术方式。
  • 两组60个月DFS、OS和CSS相同,按T分期比较亦无差异。
  • 该方案可保留呼吸、发声和吞咽等基本功能。

核心结论

  • 新辅助化疗使功能预后差或初始不适合器官保留的患者能够接受保守手术,且肿瘤学安全。

主要发现

  • 两组在性别、肿瘤部位、组织学诊断、TNM分期、复发或器官保留方面无统计学差异。
  • 两组60个月无病生存、总生存和癌症特异性生存相同。
  • 按T分期比较诱导化疗组与非诱导化疗组的DFS、OS和CSS,无统计学差异。

临床怎么用

  • 对于功能预后差或初始不适合器官保留的喉癌患者,可考虑新辅助化疗后行环状软骨上部分喉切除术以保留器官和基本功能。

局限性

  • 本研究为回顾性分析,证据等级为3。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES/HYPOTHESIS: To demonstrate that a group of patients who are not considered candidates for organ preservation can achieve organ preservation through neoadjuvant chemotherapy + surgery and to determine if there are differences regarding organ preservation, disease-free survival (DFS), overall survival (OS), and cancer-specific survival (CSS) after comparing such group with another one undergoing standard treatment. METHODS: Patients with laryngeal cancer were retrospectively analyzed and divided into two groups. Group A included patients who were initially treated with supracricoid laryngectomy. Group B included patients with T3N0 glottic squamous cell carcinoma with arytenoid fixation. Patients were offered neoadjuvant chemotherapy. Both groups underwent bilateral selective neck dissection of lymph nodes (II-V) and intentional search of the Delphian lymph nodes. RESULTS: Thirty-four patients were assigned to group A of surgery alone, and 16 patients were included in group B of induction chemotherapy. No statistical differences were found regarding sex, tumor localization, histological diagnosis, TNM staging, recurrence, or organ preservation. DFS, OS, and CSS at 60 months were the same in both groups. No statistical differences were found when comparing induction versus noninduction groups according to the T-stage in DFS, OS, and CSS. CONCLUSIONS: Neoadjuvant chemotherapy allows to perform conservative surgery in patients with poor functional prognosis or who are not good candidates for organ preservation at first. We could perform safe surgery, and there was no more recurrence. Hence DFS is not modified (i.e., there was no more recurrence); consequently, OS and CSS are not affected. Neoadjuvant chemotherapy plus supracricoid partial laryngectomy-cricohyoidoepiglottopexy is an oncologically safe procedure that preserves basic functions such as breathing, phonation, and swallowing. LEVEL OF EVIDENCE: 3 Laryngoscope, 132:156-162, 2022.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Luna-Ortiz K, Reynoso-Noveron N, Zacarias-Ramon LC, et al. Supracricoid Partial Laryngectomy With and Without Neoadjuvant Chemotherapy in Glottic Cancer. Laryngoscope. 2021. PMID: 34173978. doi:10.1002/lary.29713

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。